A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

Overview

This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.

SparkCures ID 856
Trial Phase Phase 1
Enrollment 75 Patients
Treatments
  • SGN-CD352A
Trial Sponsors
  • Seattle Genetics
NCT Identifier

NCT02954796

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG] ).
  • Age 18 years or older.
  • An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • Life expectancy greater than months.
  • Received at least 2 prior lines of therapy for MM including an immunomodulatory drug and a proteasome inhibitor.
  • Measurable disease, as defined by at least one of the following: Serum M protein 0.5 g/dL or higher, Urine M protein 200 mg/24 hr or higher, Abnormal serum free light chain (SFLC) ratio.
  • Adequate hematologic, renal, and hepatic function
  • A negative pregnancy test (for females of childbearing potential).
  • Patients must provide written informed consent.

Exclusion Criteria:

  • Other invasive malignancy within the past 3 years.
  • Active cerebral/meningeal disease related to the underlying malignancy.
  • Active Grade 3 or higher infection.
  • Known to be positive for HIV or known to have active hepatitis B or C.
  • Previous allogeneic stem cell transplant.
  • Idiopathic interstitial pneumonia or impaired diffusion capacity of the lung for carbon monoxide (DLCO).
  • Cerebrovascular or cardiovascular event, or congestive heart failure within the last 6 months.
  • Females who are pregnant or breastfeeding.

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers